HDT Bio

HDT Bio

Biotechnology Research

Seattle, Washington 5,590 followers

Immune Therapy For All

About us

HDT Bio is a vaccine and immunotherapy Biotechnology company developing drugs for immunotherapy of cancers and infectious diseases with next-generation approaches designed to enable the body’s immune system to prevent and cure disease. We have engineered our technologies to Access, Activate, and Amplify the immune system’s natural ability to create antibodies and T-cells that fight cancer and infectious diseases such as SARS-CoV-2. We are developing multiple product candidates from our proprietary discovery platforms, including LION™, which has the potential to provide health benefits to a broad patient population. Our products are designed to be cost-effective solutions to unmet medical needs and complementary to existing, cutting-edge immunotherapies. HDT Bio offers a comprehensive compensation plan which includes health insurance for employees and dependents (inclusive of multiple plants to choose from, including a $0 premium plan with HSA and company contribution), generous PTO (11 observed holidays and week long year-end closure), stock options with Carta Tax Advisory for equity and tax support, flexible spending accounts (FSAs), commuting benefits (ORCA or paid parking), and retirement benefits with company match. HDT Bio Corp. is an equal opportunity employer committed to a diverse and inclusive workforce. This environment is encouraged by HDT's culture, which supports women in science through our Women+ group, creates inclusive events to highlight the diverse cultures represented by our staff, and with the adoption of an open office environment for all.

Website
http://hdt.bio
Industry
Biotechnology Research
Company size
11-50 employees
Headquarters
Seattle, Washington
Type
Privately Held
Founded
2018
Specialties
Immunology, Virology, Oncology, Infectious Disease, and R&D

Locations

Employees at HDT Bio

Updates

Similar pages

Browse jobs

Funding

HDT Bio 7 total rounds

Last Round

Grant

US$ 1.0M

Investors

BLUE KNIGHT
See more info on crunchbase